We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Blood Test Offers Affordable and Accurate Early Detection of Lung Cancer

By LabMedica International staff writers
Posted on 08 Oct 2025

Lung cancer remains the leading cause of cancer-related deaths worldwide, largely because most cases are diagnosed at advanced stages when treatment options are limited. More...

Early detection significantly improves survival, yet current screening methods like low-dose CT (LDCT) scans are expensive, inaccessible in many regions, and prone to high false-positive rates. Now, a new blood-based test offers an affordable, accurate, and non-invasive solution capable of detecting lung cancer early and reducing unnecessary imaging procedures.

SeekIn Inc. (San Diego, CA, USA) has developed LungCanSeek, a novel diagnostic test that uses four protein markers, namely CEA, CYFRA 21-1, ProGRP, and SCCA, combined with artificial intelligence (AI) to detect lung cancer and its subtypes. The test integrates standard laboratory techniques and widely available reagents, making it simple and cost-efficient to implement globally. A multicenter study, which enrolled 1,814 participants, including 1,095 lung cancer patients, validated its accuracy and affordability across diverse populations.

In the study, the researchers analyzed blood samples for four protein markers. The AI-driven algorithm combined protein marker levels with participant age and gender to detect lung cancer and its subtypes. This approach enabled accurate identification of lung cancer presence and subtype classification, distinguishing between lung adenocarcinoma (LUAD), squamous cell carcinoma (LUSC), and small cell lung cancer (SCLC). The test’s performance was assessed across both early and late stages of the disease.

The results, published in Translational Lung Cancer Research, showed that LungCanSeek achieved 83.5% sensitivity and 90.3% specificity for lung cancer detection, with a 77.4% accuracy rate in classifying subtypes. Sensitivity for early-stage cancers reached 67.2%, marking a critical step toward improving survival through earlier intervention. The study also demonstrated the test’s cost-effectiveness, estimating reagent expenses at only USD15 per test, which is significantly lower than traditional imaging-based screenings.

A two-step screening model was proposed in which high-risk individuals undergo LungCanSeek testing first, and only positive cases proceed to LDCT scans. This approach reduced false positives by more than tenfold and cut screening costs by 2.5 times compared to LDCT alone. The method has the potential to transform large-scale screening programs, particularly in low- and middle-income countries where access to advanced imaging is limited.

The researchers noted that the technology could be seamlessly integrated into national cancer screening programs, boosting early detection rates while easing healthcare system burdens. Its simplicity, high diagnostic precision, and affordability make it a viable candidate for global implementation and a cornerstone of future preventive oncology strategies.

“LungCanSeek’s performance surpasses many existing blood-based and imaging-only screening approaches,” said Dr. Mao Mao, Founder and CEO of SeekIn Inc. “Its affordability and ease of use make it especially valuable for expanding early lung cancer detection in resource-constrained settings.”

Related Links:
SeekIn Inc


New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Collection and Transport System
PurSafe Plus®
Sample Transportation System
Tempus1800 Necto
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The TriVerity IVD test includes the TriVerity cartridge and the Myrna instrument (Photo courtesy of Inflammatix)

Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients

When a patient enters the emergency department in critical condition, clinicians must rapidly decide whether the patient has an infection, whether it is bacterial or viral, and whether immediate treatment... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.